Hypertension最新文献

{"title":"PRERISK Study: A Randomized Controlled Trial Evaluating a sFlt-1/PlGF-Based Calculator for Preeclampsia Hospitalization.","authors":"Anna C M Kluivers,Rugina I Neuman,Langeza Saleh,Henk Russcher,Ingrid A Brussé,Jerome M J Cornette,Eric A P Steegers,Marijke C van der Weide,Joris van Drongelen,Ralph R Scholten,Antonius E van Herwaarden,Sanne J Gordijn,Anneke C Muller Kobold,Wessel Ganzevoort,Sharon M Wesselius,Maurits C F J de Rotte,Robert Aardenburg,Maarten Raijmakers,Willy Visser,A H Jan Danser","doi":"10.1161/hypertensionaha.124.24386","DOIUrl":"https://doi.org/10.1161/hypertensionaha.124.24386","url":null,"abstract":"BACKGROUNDA model based on the soluble Fms-like tyrosine kinase-1/placental growth factor ratio, gestational age, and the urinary protein-to-creatinine ratio (PRERISK calculator) has been developed to predict preeclampsia-related maternal-fetal complications. Here, we tested whether this model can reduce hospital admissions without increasing complication rates among women with suspected or confirmed preeclampsia.METHODSIn this multicenter, open-label, randomized controlled trial conducted at 5 Dutch medical centers, women with suspected or confirmed preeclampsia were randomly assigned to the intervention group, where admission was guided by the PRERISK score using a 5% cutoff, or to the control group receiving routine care with a concealed PRERISK score. Two co-primary outcomes were the incidence of maternal-fetal preeclampsia-related complications (noninferiority) and the proportion of women with a hospitalization ratio (=admission days/inclusion days) ≤0.05 (superiority).RESULTSThe intervention and control groups included 442 and 435 women, respectively. In the intention-to-treat analysis, complications occurred in 41.6% of the intervention group versus 39.5% of the control group (adjusted relative risk 1.06 [95% CI, 0.92-1.22]; P=0.43). The proportion of women achieving a hospitalization ratio ≤0.05 was 23.6% in the intervention group and 26.3% in the control group (adjusted relative risk, 0.89 [95% CI, 0.71-1.13]; P=0.34). The latter was comparable in the per-protocol analysis (adjusted relative risk, 0.87 [95% CI, 0.64-1.19]; P=0.38), while in this analysis, complications occurred in 47.8% of the intervention group (n=251) versus 41.7% of the control group (n=365; adjusted relative risk 1.19 [95% CI, 1.03-1.38]; P=0.02).CONCLUSIONSRoutine screening with the PRERISK score and a 5% cutoff in patients with suspected or confirmed preeclampsia does not decrease hospitalization and is therefore not recommended.REGISTRATIONURL: https://onderzoekmetmensen.nl/nl/trial/48687; Unique identifier: NL63386.078.17, NL-OMON48687.","PeriodicalId":13042,"journal":{"name":"Hypertension","volume":"20 1","pages":"827-838"},"PeriodicalIF":8.3,"publicationDate":"2025-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143846377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Left Ventricular Hypertrophy or Not Left Ventricular Hypertrophy in Women With Prior Preeclampsia.","authors":"Erik Hedström","doi":"10.1161/hypertensionaha.124.24426","DOIUrl":"https://doi.org/10.1161/hypertensionaha.124.24426","url":null,"abstract":"","PeriodicalId":13042,"journal":{"name":"Hypertension","volume":"108 1","pages":"784-786"},"PeriodicalIF":8.3,"publicationDate":"2025-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143846375","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cuffless Blood Pressure Measurement: Where Do We Actually Stand?","authors":"Ramakrishna Mukkamala,Sanjeev G Shroff,Konstantinos G Kyriakoulis,Alberto P Avolio,George S Stergiou","doi":"10.1161/hypertensionaha.125.24822","DOIUrl":"https://doi.org/10.1161/hypertensionaha.125.24822","url":null,"abstract":"Cuffless blood pressure (BP) measurement offers considerable potential for clinical practice but is a challenging technological field. Many are investigating pulse wave analysis with or without pulse arrival time in which machine learning is applied to pulsatile waveforms obtained with mobile devices (eg, wristbands, smartphones) to estimate BP. These methods generally require individual user calibration with cuff BP measurements or demographics (eg, age, sex). This calibration makes it difficult to evaluate the method's accuracy, and many studies claiming accuracy used inadequate testing procedures. Yet, publications and regulatory-cleared devices continue to rise, seemingly implying technological advancements. An update is provided on the flurry of activity in cuffless BP technologies over the last 2 to 3 years, covering the clinical need, the latest devices, recent publications based on pulse wave analysis and pulse arrival time, progress in developing validation standards for cuffless BP devices, and recent publications on other cuffless BP measurement principles. Despite the high volume of research and development, to date, there is no compelling evidence that pulse wave analysis and pulse arrival time can provide significant added value in BP measurement accuracy beyond the cuff BP or demographic data for calibration. Thus, it is reasonable to at least be skeptical of published and future studies on pulse wave analysis and pulse arrival time for cuffless BP measurement with uncertain testing procedures. It is important to focus on establishing robust validation standards for cuffless BP devices requiring individual user calibration and also pursuing cuffless and calibration-free BP measurement methodologies going forward.","PeriodicalId":13042,"journal":{"name":"Hypertension","volume":"6 1","pages":""},"PeriodicalIF":8.3,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143836493","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Asian Expert Consensus on Nocturnal Hypertension Management.","authors":"Jing Liu,Yan Li,Kei Asayama,Xin-Jun Zhang,Hao-Min Cheng,Sungha Park,Kazuomi Kario,Erkin Mirrakhimov,Ji-Guang Wang","doi":"10.1161/hypertensionaha.124.24026","DOIUrl":"https://doi.org/10.1161/hypertensionaha.124.24026","url":null,"abstract":"There is consistent and strong evidence that nighttime blood pressure is a better predictor of target organ damage and cardiovascular events, and the prevalence of nocturnal hypertension is high in all populations but higher in Asians than Europeans. Excessive salt intake and salt sensitivity have long been believed to be risk factors for elevated nighttime blood pressure in Asians. For various reasons, the control rate of nocturnal hypertension is low, for example, insufficient monitoring and inappropriate therapeutic regimens. With the increasing evidence and possibility of management, it is highly relevant to have thorough discussions among Asian experts and to reach a consensus on major aspects in regard to the management of nocturnal hypertension. The consensus involves 5 aspects, including definitions and diagnosis, epidemiology, risk and risk factors, treatment, and future perspectives.","PeriodicalId":13042,"journal":{"name":"Hypertension","volume":"26 1","pages":""},"PeriodicalIF":8.3,"publicationDate":"2025-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143822608","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Endothelial SMAD4 Deficiency Promotes Pulmonary Hypertension by Impairing Cell Adhesion and Extracellular Matrix Organization.","authors":"Wenyu Lv,Xinyu Gu,Lei Zeng,Keli Liu,Yunhua Li,Xun Chen,Xuan Zhang,Xuetong Zhou,Jiaqi He,Yong Dai,Jingfeng Wang,Feng Zhang,Yangxin Chen","doi":"10.1161/hypertensionaha.124.22782","DOIUrl":"https://doi.org/10.1161/hypertensionaha.124.22782","url":null,"abstract":"BACKGROUNDAberrant BMPR2 (bone morphogenetic protein receptor 2) signaling is associated with the pathogenesis of pulmonary hypertension. SMAD4 is an essential downstream effector of BMPR2 signaling, but whether and how it participates in pulmonary hypertension are unclear.METHODSGlobally and vascular cell-specifically inducible knockout mouse models were used to examine the role of SMAD4 deficiency in differential cell compartments in the development of pulmonary hypertension. Single-cell transcriptomic analysis in combination with in vitro cell function measurements was conducted to provide mechanistic insights into pulmonary hypertension pathogenesis.RESULTSAdult mice with Smad4 global deletion or endothelial cell-specific deletion spontaneously developed pulmonary hypertension manifestations, characterized by elevated right ventricle systolic pressure and excessive muscularization in pulmonary distal vessels, which were accompanied by other cardiovascular abnormalities. By contrast, mice with smooth muscle cell-specific Smad4 deletion had no pulmonary hypertension but rather displayed evident aortic aneurysm and dissection. At the cellular level, SMAD4 deficiency led to impairment of both endothelial cell-cell and cell-matrix adhesions and disorganized ECM (extracellular matrix), resulting in increased vascular leak and weakened endothelium-matrix attachment. Notably, endothelial Itgb1 deletion mimicked the impact of endothelial Smad4 loss on pulmonary hypertension. Finally, enhancing endothelial cell adhesion and ECM assembly by administrating an MMP (matrix metallopeptidase) inhibitor ilomastat could alleviate the pulmonary hypertension manifestations caused by endothelial SMAD4 deficiency.CONCLUSIONSSMAD4 deficiency in endothelial cells, but not smooth muscle cells, plays a pathogenic role in pulmonary hypertension, via dampening endothelial cell-cell and cell-matrix adhesions and ECM organization.","PeriodicalId":13042,"journal":{"name":"Hypertension","volume":"101 1","pages":""},"PeriodicalIF":8.3,"publicationDate":"2025-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143822609","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hypertension Management Dynamics in Pediatric CKD: Insights From the 4C Study.","authors":"Anke Doyon, Aysun Karabay Bayazit, Ali Duzova, Daniela Thurn, Nur Canpolat, Ipek Kaplan Bulut, Karolis Azukaitis, Lukasz Obrycki, Bruno Ranchin, Rukshana Shroff, Cengiz Candan, Hakan Erdogan, Dusan Paripovic, Osman Donmez, Francesca Lugani, Klaus Arbeiter, Ebru Yilmaz, Ariane Zaloszyc, Elke Wühl, Anette Melk, Uwe Querfeld, Franz Schaefer","doi":"10.1161/HYPERTENSIONAHA.124.24330","DOIUrl":"https://doi.org/10.1161/HYPERTENSIONAHA.124.24330","url":null,"abstract":"<p><strong>Background: </strong>Office blood pressure (BP) trajectories may help assess hypertension progression and the effects of antihypertensive treatment in children with chronic kidney disease.</p><p><strong>Methods: </strong>Analysis of antihypertensive treatment and BP slopes in 320 patients from the 4C study (Cardiovascular Comorbidity in Children with Chronic Kidney Disease) cohort with chronic kidney disease before renal replacement therapy, based on a minimum of 3 individual observations and 2 years of follow-up.</p><p><strong>Results: </strong>At enrollment, 70 (22%) patients had uncontrolled or untreated hypertension, 130 (41%) patients had controlled hypertension, and 120 (37%) patients had normotension without antihypertensive treatment. Antihypertensive treatment medication was prescribed for 53% of patients at baseline and initiated or added for 91 patients (AHT-I group, 28%) during follow-up. Overall BP SD score remained stable over time in the cohort (β=-0.037±0.034, <i>P</i>=0.34 and -0.029±0.348, <i>P</i>=0.093 per year for systolic and diastolic BP SD score). In the AHT-I group, systolic and diastolic BP SD scores were higher at baseline and decreased significantly during follow-up (-0.22±0.07, <i>P</i><0.003 and -0.12±0.05 SD score per year, <i>P</i>=0.01). Only 8 of 70 (11%) patients from the previously untreated/uncontrolled group remained untreated at the last observation, while 31 (44%) were controlled during follow-up. Of the 120 normotensive patients at baseline, 60% remained normotensive while 40% progressed to uncontrolled/untreated (n=23, 19%) or controlled (n=24, 20%) hypertension.</p><p><strong>Conclusions: </strong>Although the overall BP of the population remained stable over time, individual patterns of BP management showed considerable variability. BP control improved significantly with intensified antihypertensive therapy; however, a significant number of previously normotensive individuals developed new-onset hypertension during the observation period.</p>","PeriodicalId":13042,"journal":{"name":"Hypertension","volume":" ","pages":""},"PeriodicalIF":6.9,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143803271","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early Pregnancy Blood Pressure Trajectories and Hypertension Years After Pregnancy.","authors":"James M Roberts, Stacey E Alexeeff, Baiyang Sun, Mara Greenberg, Alexis King, Mai N Nguyen-Huynh, Alan S Go, Erica P Gunderson","doi":"10.1161/HYPERTENSIONAHA.125.24649","DOIUrl":"https://doi.org/10.1161/HYPERTENSIONAHA.125.24649","url":null,"abstract":"<p><strong>Background: </strong>Hypertensive disorders of pregnancy (HDP) increase cardiovascular disease risk. Blood pressure (BP) trajectories ≤20 weeks' gestation predict HDP outcomes. We hypothesized that early-pregnancy BP patterns stratify risk of developing hypertension years after pregnancy.</p><p><strong>Methods: </strong>This prospective cohort of 174 774 women without prior hypertension, kidney, liver, or heart disease, or history of preeclampsia entered prenatal care ≤14 weeks and delivered a stillborn or live singleton birth at Kaiser Permanente Northern California hospitals (2009-2019). Electronic health records provided data, including HDP for each birth, longitudinal outpatient clinical BP measurements, International Classification of Diseases codes, and medication use to identify new-onset hypertension from 2 months through 14 years post-delivery (2009-2023). Latent class trajectory modeling identified 6 BP trajectory (BPT) groups capturing both BP levels and slopes from 0 to 20 weeks' gestation. Multivariable Cox regression models estimated the hazard ratio (95% CIs) of new-onset hypertension after pregnancy associated with early-pregnancy BP trajectories, with effect modification by HDP.</p><p><strong>Results: </strong>BP trajectories were associated with an increasing gradient of hypertension risk after pregnancy within each HDP group. Adjusted hazard ratios were higher among preeclampsia and gestational hypertension groups than for no HDP. From lowest to highest BPT groups, hazard ratios ranged from 2.91 to 27.31 for preeclampsia, 4.20 to 27.81 for gestational hypertension, and 2.92 to 10.96 for no HDP compared with lowest BP trajectories of the no HDP group (all reference 1.0).</p><p><strong>Conclusions: </strong>Early-pregnancy BP trajectories are strongly associated with new-onset hypertension years after pregnancy. Combined with HDP, they may stratify risk for targeted surveillance and early interventions and improve the prediction of cardiovascular disease risk in women.</p>","PeriodicalId":13042,"journal":{"name":"Hypertension","volume":" ","pages":""},"PeriodicalIF":6.9,"publicationDate":"2025-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143763697","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Total and Free Placental Growth Factor Levels During Preeclampsia and Fetal Growth Restriction.","authors":"A Jungelson, A Ridoux, M Barthe, D Redel, H Abbas, B Haddad, S A Karumanchi, Edouard Lecarpentier","doi":"10.1161/HYPERTENSIONAHA.125.24736","DOIUrl":"https://doi.org/10.1161/HYPERTENSIONAHA.125.24736","url":null,"abstract":"<p><strong>Background: </strong>The objective of this study was to evaluate total circulating PlGF (placental growth factor) and free PlGF concentrations to provide insights into the mechanisms of decreased PlGF noted in preeclampsia and fetal growth restriction.</p><p><strong>Methods: </strong>We conducted a retrospective single-center study in pregnant women receiving care for suspected preeclampsia and/or fetal growth. Serum angiogenic proteins (sFLT1 [soluble fms-like tyrosine kinase] and free PlGF) were measured on an automated platform as part of standard-of-care. Total PlGF concentrations in the serum were directly measured using a validated biochemical procedure that dissociated circulating sFLT1 and PlGF complexes. Small for gestational age (SGA) was defined by birthweight ≤10th percentile.</p><p><strong>Results: </strong>Of the 407 women studied, 155 women did not develop preeclampsia or SGA (control group), 111 women developed SGA without preeclampsia (SGA group), 71 women developed preeclampsia without SGA (preeclampsia group), and 70 developed preeclampsia and SGA (preeclampsia+SGA group). Despite reductions in free PlGF levels (229 [158-321] pg/mL), total PlGF levels were not reduced in the preeclampsia group (1020 [738-1444] pg/mL) compared with the control group (1077 [763-1595] pg/mL). In contrast, the total PlGF levels were significantly reduced in the SGA group (744 [462-1161] pg/mL; <i>P</i><0.0001) and the preeclampsia +SGA group (616 [349-917] pg/mL; <i>P</i><0.0001) compared with the control group (1077 [763-1595] pg/mL).</p><p><strong>Conclusions: </strong>Placental dysfunction associated with preeclampsia, characterized by reduced free PlGF levels but unchanged total PlGF, is driven by excessive placental production of sFLT1. Placental dysfunction associated with SGA, marked by reductions in both free and total PlGF, is mediated by decreased placental PlGF production.</p>","PeriodicalId":13042,"journal":{"name":"Hypertension","volume":" ","pages":""},"PeriodicalIF":6.9,"publicationDate":"2025-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143763651","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preeclamptic Placental CD19+ B Cells Are Causal to Hypertension During Pregnancy.","authors":"Owen Herrock, Nathan Campbell, Evangeline Deer, Lorena M Amaral, Darby Whitney, Rachael Morris, Kedra Wallace, Ty Turner, E Hawthorne Cleveland, Sheila Belk, George W Booz, Denise C Cornelius, Babbette LaMarca","doi":"10.1161/HYPERTENSIONAHA.124.24552","DOIUrl":"https://doi.org/10.1161/HYPERTENSIONAHA.124.24552","url":null,"abstract":"<p><strong>Background: </strong>Patients with preeclampsia exhibit hypertension and chronic inflammation characterized by CD (cluster determinant) 4+T cells, B cells secreting AT1-AA (agonistic autoantibody against the angiotensin II type 1 receptor), inflammatory cytokines, and complement activation. Importantly, a history of COVID-19 during pregnancy is associated with an increased incidence of a preeclampsia-like phenotype and is partly mediated by CD4+T cells. We recently showed pregnant patients with a history of COVID-19 with or without preeclampsia produce AT1-AA, indicating the importance of B lymphocytes in the progression of preeclampsia and possibly of COVID-19. Therefore, we hypothesize that B cells from patients with preeclampsia with or without COVID-19 history induce the preeclampsia phenotype through AT1-AA.</p><p><strong>Methods: </strong>Placental B cells were isolated from normal pregnant, patients with preeclampsia, normotensive COVID-19 history, or preeclampsia COVID-19 history at delivery. Then, 3×10⁵ B cells were transferred intraperitoneally into pregnant athymic rats at gestational day 12. On gestational day 18, carotid catheters were inserted. On gestational day 19, mean arterial pressure was measured, and tissues were collected.</p><p><strong>Results: </strong>Preeclampsia B-cell recipients had significantly increased mean arterial pressure, AT1-AA, inflammatory cytokines, and complement activation compared with normal pregnant B-cell recipients. Recipients of B cells with COVID-19 history had markers of inflammation and hypertension but not to the level of significance as recipients of preeclampsia B cells. Inhibition of AT1-AA attenuated the hypertension that occurred in response to preeclampsia or preeclampsia B cells with COVID-19 history.</p><p><strong>Conclusions: </strong>This study demonstrates the important role of B cells in contributing to hypertension and chronic inflammation during preeclampsia with or without COVID-19 history through secretion of AT1-AA.</p>","PeriodicalId":13042,"journal":{"name":"Hypertension","volume":" ","pages":""},"PeriodicalIF":6.9,"publicationDate":"2025-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143763648","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Disparities in Postpartum Care After a Hypertensive Disorder of Pregnancy in the United States.","authors":"Megan M McLaughlin, Neda Ghaffari, Catherine Lee, Malamo E Countouris, Phoebe Ashley, Amanda Schnell-Herringer, Divya P Mallampati, Juan M Gonzalez, Alexis L Beatty","doi":"10.1161/HYPERTENSIONAHA.124.24569","DOIUrl":"https://doi.org/10.1161/HYPERTENSIONAHA.124.24569","url":null,"abstract":"<p><strong>Background: </strong>The postpartum period is a critical time for blood pressure monitoring and cardiovascular risk factor modification in individuals with hypertensive disorders of pregnancy (HDP), who are at increased risk for cardiovascular disease.</p><p><strong>Methods: </strong>We analyzed data from the Pregnancy Risk Assessment Monitoring System, a nationally representative US population-based survey of postpartum women with live births from 2016 to 2022. Among individuals with HDP, we evaluated the association between race, ethnicity, and other socioeconomic factors and (1) postpartum visit attendance and (2) postpartum counseling/screening.</p><p><strong>Results: </strong>Among 42 858 participants with HDP (weighted n=2 011 284), 90% reported attending a postpartum visit. Adjusting for other factors, Hispanic individuals (odds ratio, 0.75 [95% CI, 0.60-0.94]), non-Hispanic Black individuals (odds ratio, 0.75 [95% CI, 0.62-0.91]), and individuals of other or multiple races (odds ratio, 0.57 [95% CI, 0.44-0.74]) were less likely to attend a postpartum visit, compared with non-Hispanic White individuals. Individuals with lower income, lower educational attainment, and those with Medicaid or no insurance were significantly less likely to report attending a postpartum visit. Among those who reported attending a postpartum visit, only 56.3% reported receiving postpartum counseling on healthy lifestyle, 60.9% reported receiving screening for cigarette smoking, and 23.7% reported receiving testing for diabetes.</p><p><strong>Conclusions: </strong>Most individuals with HDP reported attending a postpartum visit, but there were significant disparities in postpartum visit attendance by race/ethnicity, health insurance, and socioeconomic status. In addition, many participants reported not receiving postpartum counseling or screening for cardiovascular risk factors. This represents a missed opportunity to equitably improve the long-term cardiovascular health of individuals with HDP.</p>","PeriodicalId":13042,"journal":{"name":"Hypertension","volume":" ","pages":""},"PeriodicalIF":6.9,"publicationDate":"2025-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143763693","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}